董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anthony Viscogliosi | 男 | Director | 63 | 2.50万美元 | 未持股 | 2026-06-30 |
| Ali Abdullah Al Amri | 男 | Director | 33 | 2.50万美元 | 未持股 | 2026-06-30 |
| Deepankar Panigrahi | 男 | Director | 47 | 2.50万美元 | 未持股 | 2026-06-30 |
| Marc Viscogliosi | 男 | Director | 51 | 2.50万美元 | 未持股 | 2026-06-30 |
| Robert Donohue | 男 | Director | 78 | 2.50万美元 | 未持股 | 2026-06-30 |
| Craig Greener | 男 | Director | 55 | 2.50万美元 | 未持股 | 2026-06-30 |
| Dirk Kuyper | 男 | Director | 69 | 5.00万美元 | 未持股 | 2026-06-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Peter Ringwood | 男 | Vice President, Operations | 60 | 未披露 | 未持股 | 2026-06-30 |
| Jason Hoffman | 男 | Vice President, Business and Market Development | 54 | 未披露 | 未持股 | 2026-06-30 |
| James Kuras | 男 | Vice President, Clinical, Regulatory and Quality Affairs | 62 | 未披露 | 未持股 | 2026-06-30 |
| Varun Gandhi | 男 | Chief Financial Officer | 42 | 78.11万美元 | 未持股 | 2026-06-30 |
| Fadel Ghossein | 男 | Vice President, International | 47 | 未披露 | 未持股 | 2026-06-30 |
| Steven Murray | 男 | Chief Executive Officer | 65 | 100.88万美元 | 未持股 | 2026-06-30 |
| Steven Sanderson | 男 | Vice President, Marketing and Product Development | 59 | 未披露 | 未持股 | 2026-06-30 |
| Jeanina Bradley | 女 | Vice President,Sales | 49 | 未披露 | 未持股 | 2026-06-30 |
| Vincent Lesniewski | 男 | Vice President, Medical Education and Clinical Accounts | 54 | 未披露 | 未持股 | 2026-06-30 |
董事简历
中英对照 | 中文 | 英文- Anthony Viscogliosi
-
Anthony Viscogliosi自Centinel成立以来一直担任董事，其身份是Centinel董事会中Viscogliosi Brothers，LLC的代表。自1999年8月起，h.c. Anthony Viscogliosi博士担任VB的负责人之一。自2025年4月成立以来，h.c. Anthony Viscogliosi博士一直担任VB附属公司VB Spine的联合首席执行官。h.c. Anthony Viscogliosi博士还曾在后脊柱非融合解决方案提供商Companion Spine，LLC任职，自2020年9月起担任董事会成员，自2025年4月起担任执行主席兼首席执行官；自2026年3月起担任Nuvaira Inc.的董事，该公司是一家开发肺部疾病疗法的公司。H.C. Anthony Viscogliosi博士还担任哈特福德俱乐部主席。h.c. Anthony Viscogliosi博士自2004年4月起担任MCRA，LLC的董事会成员，MCRA，LLC是一家面向医疗技术开发商的咨询公司和临床研究组织（CRO），直至2024年7月将其出售给艾昆纬。h.c. Anthony Viscogliosi博士还在2018年8月至2024年7月期间担任MCRA首席执行官。Anthony Viscogliosi先生于2007年12月至2020年6月担任Woven Orthopedic Technologies，LLC的执行主席，目前担任董事会成员，该公司是一家骨科专科公司，专注于加强受损骨中的骨科植入物固定。h.c. Anthony Viscogliosi博士毕业于哈佛医学院全球医疗保健领导者证书课程，获得纽约足病医学学院荣誉博士学位，获得曼彻斯特社区学院荣誉AB学位，毕业于美国海军供应军团学校，就读于海军战争学院，就读于武装部队参谋学院和国防大学，获得密歇根大学迪尔伯恩分校经济学学士学位，曾在美国海军预备役中担任军官，在服役20年后担任中尉指挥官，他的最后一个单位隶属于海军情报办公室1201. h.c. Anthony Viscogliosi有资格在Centinel Spine Holdco，Inc.的董事会任职，因为他在领导、管理和医疗器械行业拥有丰富的经验，他在风险投资行业的角色，以及他对Centinel Spine Holdco，Inc.业务的了解。
Anthony Viscogliosi has served as a director of Centinel since its formation in his capacity as a representative of Viscogliosi Brothers, LLC on Centinel's board. Since August 1999, Dr. h.c. Anthony Viscogliosi has served as one of the Principals of VB. Dr. h.c. Anthony Viscogliosi has served as a Co Chief Executive Officer of VB Spine, an affiliate of VB, since its formation in April 2025. Dr. h.c. Anthony Viscogliosi has also served at Companion Spine, LLC, a provider of posterior spine non fusion solutions, as a member of its board since September 2020 and as its Executive Chairman and Chief Executive Officer since April 2025; as a director of Nuvaira Inc., a company developing therapies for lung disease, since March 2026. Dr. h.c. Anthony Viscogliosi also serves as President of The Hartford Club. Dr. h.c. Anthony Viscogliosi served as a member of the board of managers of MCRA, LLC, an advisory firm and clinical research organization (CRO) to medical technology developers, from April 2004 until its sale to IQVIA in July 2024. Dr. h.c. Anthony Viscogliosi also served as Chief Executive Officer of MCRA from August 2018 until July 2024. Mr. Anthony Viscogliosi served as Executive Chairman from December 2007 to June 2020, and currently serves as a member of the board, of Woven Orthopedic Technologies, LLC, an orthogeriatric specialty company that focuses on enhancing orthopedic implant fixation in compromised bone. Dr. h.c. Anthony Viscogliosi graduated in the certificate program for Global Healthcare Leaders from Harvard Medical School, received a Dr. honoris causa from New York College of Podiatric Medicine, received an AB honoris causa from Manchester Community College, graduated from the United States Navy Supply Corps School, attended the Naval War College, attended the Armed Forces Staff College and National Defense University, received a B.A. in Economics from the University of Michigan, Dearborn, and served as an officer in the United States Navy Reserve, separating after 20 years of services as a Lieutenant Commander, with his last unit affiliation being the Office of Naval Intelligence 1201. h.c. - Anthony Viscogliosi自Centinel成立以来一直担任董事，其身份是Centinel董事会中Viscogliosi Brothers，LLC的代表。自1999年8月起，h.c. Anthony Viscogliosi博士担任VB的负责人之一。自2025年4月成立以来，h.c. Anthony Viscogliosi博士一直担任VB附属公司VB Spine的联合首席执行官。h.c. Anthony Viscogliosi博士还曾在后脊柱非融合解决方案提供商Companion Spine，LLC任职，自2020年9月起担任董事会成员，自2025年4月起担任执行主席兼首席执行官；自2026年3月起担任Nuvaira Inc.的董事，该公司是一家开发肺部疾病疗法的公司。H.C. Anthony Viscogliosi博士还担任哈特福德俱乐部主席。h.c. Anthony Viscogliosi博士自2004年4月起担任MCRA，LLC的董事会成员，MCRA，LLC是一家面向医疗技术开发商的咨询公司和临床研究组织（CRO），直至2024年7月将其出售给艾昆纬。h.c. Anthony Viscogliosi博士还在2018年8月至2024年7月期间担任MCRA首席执行官。Anthony Viscogliosi先生于2007年12月至2020年6月担任Woven Orthopedic Technologies，LLC的执行主席，目前担任董事会成员，该公司是一家骨科专科公司，专注于加强受损骨中的骨科植入物固定。h.c. Anthony Viscogliosi博士毕业于哈佛医学院全球医疗保健领导者证书课程，获得纽约足病医学学院荣誉博士学位，获得曼彻斯特社区学院荣誉AB学位，毕业于美国海军供应军团学校，就读于海军战争学院，就读于武装部队参谋学院和国防大学，获得密歇根大学迪尔伯恩分校经济学学士学位，曾在美国海军预备役中担任军官，在服役20年后担任中尉指挥官，他的最后一个单位隶属于海军情报办公室1201. h.c. Anthony Viscogliosi有资格在Centinel Spine Holdco，Inc.的董事会任职，因为他在领导、管理和医疗器械行业拥有丰富的经验，他在风险投资行业的角色，以及他对Centinel Spine Holdco，Inc.业务的了解。
- Anthony Viscogliosi has served as a director of Centinel since its formation in his capacity as a representative of Viscogliosi Brothers, LLC on Centinel's board. Since August 1999, Dr. h.c. Anthony Viscogliosi has served as one of the Principals of VB. Dr. h.c. Anthony Viscogliosi has served as a Co Chief Executive Officer of VB Spine, an affiliate of VB, since its formation in April 2025. Dr. h.c. Anthony Viscogliosi has also served at Companion Spine, LLC, a provider of posterior spine non fusion solutions, as a member of its board since September 2020 and as its Executive Chairman and Chief Executive Officer since April 2025; as a director of Nuvaira Inc., a company developing therapies for lung disease, since March 2026. Dr. h.c. Anthony Viscogliosi also serves as President of The Hartford Club. Dr. h.c. Anthony Viscogliosi served as a member of the board of managers of MCRA, LLC, an advisory firm and clinical research organization (CRO) to medical technology developers, from April 2004 until its sale to IQVIA in July 2024. Dr. h.c. Anthony Viscogliosi also served as Chief Executive Officer of MCRA from August 2018 until July 2024. Mr. Anthony Viscogliosi served as Executive Chairman from December 2007 to June 2020, and currently serves as a member of the board, of Woven Orthopedic Technologies, LLC, an orthogeriatric specialty company that focuses on enhancing orthopedic implant fixation in compromised bone. Dr. h.c. Anthony Viscogliosi graduated in the certificate program for Global Healthcare Leaders from Harvard Medical School, received a Dr. honoris causa from New York College of Podiatric Medicine, received an AB honoris causa from Manchester Community College, graduated from the United States Navy Supply Corps School, attended the Naval War College, attended the Armed Forces Staff College and National Defense University, received a B.A. in Economics from the University of Michigan, Dearborn, and served as an officer in the United States Navy Reserve, separating after 20 years of services as a Lieutenant Commander, with his last unit affiliation being the Office of Naval Intelligence 1201. h.c.
- Ali Abdullah Al Amri
-
Ali Abdullah Al Amri作为Delac Spine Inc.在Centinel董事会的代表，自2023年7月起担任Centinel的董事。Al Amri先生自2014年7月起担任阿曼投资管理局私人市场经理，该机构是阿曼苏丹国的主权财富基金，也是Delac Spine Inc.的唯一股东。在此期间，他处理了横跨北美、欧洲和亚洲的医疗保健、技术和能源转型领域的资产和投资组合。此外，自2022年3月起，Al Amri先生担任Oman Chlorine S.A.O.G.和National Pharmaceutical Industries Co.（SAOC）的董事，这两家公司都是在马斯喀特证券交易所上市的上市公司，以及私营公司BioGenomics Limited。Al Amri先生获得布拉德福德大学会计和金融学士学位。Al Amri有资格在Centinel Spine Holdco，Inc.的董事会任职，因为他的投资和金融经验以及对Centinel Spine Holdco，Inc.业务的了解。
Ali Abdullah Al Amri has served as a director of Centinel since July 2023 in his capacity as a representative of Delac Spine Inc. on Centinel's board. Mr. Al Amri has served as Manager, Private Markets for the Oman Investment Authority, a sovereign wealth fund of the Sultanate of Oman and sole stockholder of Delac Spine Inc., since July 2014. During this time, he has handled a portfolio of assets and investments across the healthcare, technology, and energy transition sectors in North America, Europe, and Asia. In addition, since March 2022, Mr. Al Amri has served as a director of Oman Chlorine S.A.O.G. and National Pharmaceutical Industries Co. (SAOC), both public companies listed on the Muscat Stock Exchange, and BioGenomics Limited, a private company. Mr. Al Amri received a B.Sc. in Accounting and Finance from the University of Bradford. - Ali Abdullah Al Amri作为Delac Spine Inc.在Centinel董事会的代表，自2023年7月起担任Centinel的董事。Al Amri先生自2014年7月起担任阿曼投资管理局私人市场经理，该机构是阿曼苏丹国的主权财富基金，也是Delac Spine Inc.的唯一股东。在此期间，他处理了横跨北美、欧洲和亚洲的医疗保健、技术和能源转型领域的资产和投资组合。此外，自2022年3月起，Al Amri先生担任Oman Chlorine S.A.O.G.和National Pharmaceutical Industries Co.（SAOC）的董事，这两家公司都是在马斯喀特证券交易所上市的上市公司，以及私营公司BioGenomics Limited。Al Amri先生获得布拉德福德大学会计和金融学士学位。Al Amri有资格在Centinel Spine Holdco，Inc.的董事会任职，因为他的投资和金融经验以及对Centinel Spine Holdco，Inc.业务的了解。
- Ali Abdullah Al Amri has served as a director of Centinel since July 2023 in his capacity as a representative of Delac Spine Inc. on Centinel's board. Mr. Al Amri has served as Manager, Private Markets for the Oman Investment Authority, a sovereign wealth fund of the Sultanate of Oman and sole stockholder of Delac Spine Inc., since July 2014. During this time, he has handled a portfolio of assets and investments across the healthcare, technology, and energy transition sectors in North America, Europe, and Asia. In addition, since March 2022, Mr. Al Amri has served as a director of Oman Chlorine S.A.O.G. and National Pharmaceutical Industries Co. (SAOC), both public companies listed on the Muscat Stock Exchange, and BioGenomics Limited, a private company. Mr. Al Amri received a B.Sc. in Accounting and Finance from the University of Bradford.
- Deepankar Panigrahi
-
Deepankar Panigrahi自2018年2月起担任Centinel的董事，担任Centinel董事会Delac Spine Inc.的代表。Panigrahi先生自2015年2月起在阿曼投资局工作，该机构是阿曼苏丹国的主权财富基金，也是Delac Spine Inc.的唯一股东，现任董事—— Private Markets。在此期间，他广泛参与了一系列领域的私募股权投资，主要是医疗保健、技术和以全球为重点的基础设施。此外，自2021年4月起，他担任阿曼印度联合投资基金的董事。Panigrahi先生获得了剑桥大学的工商管理硕士学位，以及密歇根大学安娜堡分校的信息经济学、管理和政策硕士学位和经济学学士学位。此外，他还拥有CFA称号。Panigrahi有资格在Centinel Spine Holdco，Inc.的董事会任职，因为他有投资和金融经验，并且对Centinel Spine Holdco，Inc.的业务有了解。
Deepankar Panigrahi has served as a director of Centinel since February 2018 in his capacity as a representative of Delac Spine Inc. on Centinel's board. Mr. Panigrahi has worked for the Oman Investment Authority, a sovereign wealth fund of the Sultanate of Oman and sole stockholder of Delac Spine Inc., since February 2015 and is currently the Director—Private Markets. During this time, he has been extensively involved in private equity investments across a range of sectors primarily healthcare, technology and infrastructure with a global focus. In addition, since April 2021 he has served as a director of the Oman India Joint Investment Fund. Mr. Panigrahi received an M.B.A. from the University of Cambridge, and an M.S. in Information Economics, Management and Policy, and a B.A. in Economics from the University of Michigan, Ann Arbor. In addition, he holds the CFA designation. - Deepankar Panigrahi自2018年2月起担任Centinel的董事，担任Centinel董事会Delac Spine Inc.的代表。Panigrahi先生自2015年2月起在阿曼投资局工作，该机构是阿曼苏丹国的主权财富基金，也是Delac Spine Inc.的唯一股东，现任董事—— Private Markets。在此期间，他广泛参与了一系列领域的私募股权投资，主要是医疗保健、技术和以全球为重点的基础设施。此外，自2021年4月起，他担任阿曼印度联合投资基金的董事。Panigrahi先生获得了剑桥大学的工商管理硕士学位，以及密歇根大学安娜堡分校的信息经济学、管理和政策硕士学位和经济学学士学位。此外，他还拥有CFA称号。Panigrahi有资格在Centinel Spine Holdco，Inc.的董事会任职，因为他有投资和金融经验，并且对Centinel Spine Holdco，Inc.的业务有了解。
- Deepankar Panigrahi has served as a director of Centinel since February 2018 in his capacity as a representative of Delac Spine Inc. on Centinel's board. Mr. Panigrahi has worked for the Oman Investment Authority, a sovereign wealth fund of the Sultanate of Oman and sole stockholder of Delac Spine Inc., since February 2015 and is currently the Director—Private Markets. During this time, he has been extensively involved in private equity investments across a range of sectors primarily healthcare, technology and infrastructure with a global focus. In addition, since April 2021 he has served as a director of the Oman India Joint Investment Fund. Mr. Panigrahi received an M.B.A. from the University of Cambridge, and an M.S. in Information Economics, Management and Policy, and a B.A. in Economics from the University of Michigan, Ann Arbor. In addition, he holds the CFA designation.
- Marc Viscogliosi
-
Marc Viscogliosi自2020年3月起担任Centinel的董事，担任Centinel董事会Viscogliosi Brothers，LLC的代表。自1999年4月起，Marc Viscogliosi先生担任VB的负责人。Marc Viscogliosi先生自VB Spine于2025年4月成立以来一直担任联合首席执行官。自2016年10月以来，Marc Viscogliosi先生一直担任Spine Biopharma，LLC的董事长兼首席执行官，该公司是一家专门从事非手术疗法的公司，可在不使用阿片类药物的情况下减缓或阻止病理性脊柱疾病进展。此外，Marc Viscogliosi先生此前曾于2004年8月至2019年3月担任非融合和融合脊柱植入解决方案的骨科供应商Paradigm Spine，LLC的董事长兼首席执行官，并于2004年4月至2018年8月担任MCRA的首席执行官。Marc Viscogliosi先生获得纽约大学经济学和政治学学士学位。Marc Viscogliosi有资格在Centinel Spine Holdco，Inc.的董事会任职，因为他在医疗器械公司拥有丰富的经验、投资经验以及对Centinel Spine Holdco，Inc.业务的了解。
Marc Viscogliosi has served as a director of Centinel since March 2020 in his capacity as a representative of Viscogliosi Brothers, LLC on Centinel's board. Since April 1999, Mr. Marc Viscogliosi has served as a Principal of VB. Mr. Marc Viscogliosi has served as a Co Chief Executive Officer of VB Spine since its formation in April 2025. Mr. Marc Viscogliosi has served as Chairman and Chief Executive Officer of Spine Biopharma, LLC, a company specializing in non surgical therapies that slow or stop pathological spinal disease progression without the use of opioids, since October 2016. In addition, Mr. Marc Viscogliosi previously served as Chairman and Chief Executive Officer of Paradigm Spine, LLC, an orthopedic provider of non fusion and fusion spinal implant solutions from August 2004 to March 2019, and as Chief Executive Officer of MCRA from April 2004 to August 2018. Mr. Marc Viscogliosi received a B.A. in Economics and Political Science from New York University. - Marc Viscogliosi自2020年3月起担任Centinel的董事，担任Centinel董事会Viscogliosi Brothers，LLC的代表。自1999年4月起，Marc Viscogliosi先生担任VB的负责人。Marc Viscogliosi先生自VB Spine于2025年4月成立以来一直担任联合首席执行官。自2016年10月以来，Marc Viscogliosi先生一直担任Spine Biopharma，LLC的董事长兼首席执行官，该公司是一家专门从事非手术疗法的公司，可在不使用阿片类药物的情况下减缓或阻止病理性脊柱疾病进展。此外，Marc Viscogliosi先生此前曾于2004年8月至2019年3月担任非融合和融合脊柱植入解决方案的骨科供应商Paradigm Spine，LLC的董事长兼首席执行官，并于2004年4月至2018年8月担任MCRA的首席执行官。Marc Viscogliosi先生获得纽约大学经济学和政治学学士学位。Marc Viscogliosi有资格在Centinel Spine Holdco，Inc.的董事会任职，因为他在医疗器械公司拥有丰富的经验、投资经验以及对Centinel Spine Holdco，Inc.业务的了解。
- Marc Viscogliosi has served as a director of Centinel since March 2020 in his capacity as a representative of Viscogliosi Brothers, LLC on Centinel's board. Since April 1999, Mr. Marc Viscogliosi has served as a Principal of VB. Mr. Marc Viscogliosi has served as a Co Chief Executive Officer of VB Spine since its formation in April 2025. Mr. Marc Viscogliosi has served as Chairman and Chief Executive Officer of Spine Biopharma, LLC, a company specializing in non surgical therapies that slow or stop pathological spinal disease progression without the use of opioids, since October 2016. In addition, Mr. Marc Viscogliosi previously served as Chairman and Chief Executive Officer of Paradigm Spine, LLC, an orthopedic provider of non fusion and fusion spinal implant solutions from August 2004 to March 2019, and as Chief Executive Officer of MCRA from April 2004 to August 2018. Mr. Marc Viscogliosi received a B.A. in Economics and Political Science from New York University.
- Robert Donohue
-
Robert Donohue自2017年12月起担任Centinel董事，担任Centinel董事会AW Alpha Capital LLC代表。Donohue先生自2017年11月起担任私人投资集团WJFS，Inc.的关联公司AW Alpha Capital LLC的经理。自2014年1月起，Donohue先生担任WJFS，Inc.的首席执行官兼首席财务官。从1998年至2012年6月，Donohue先生担任Synthes，Inc.的首席财务官职务，该公司以前是一家在瑞士六家交易所上市的公立医疗器械制造商。此外，从1997年到2012年6月，Donohue先生担任Synthes，Inc.的子公司Synthes Canada，Ltd.的总裁职务。Donohue先生于1990年在Synthes（USA）开始担任公司财务总监，此后不久晋升为财务副总裁。在加入Synthes之前，他曾在多个财务岗位任职，包括在几家美国大公司担任公司财务总监和工厂总监。除了在Centinel的董事会席位外，Donohue先生还曾在生命科学行业的两家私营公司的董事会任职，或服务于生命科学行业，Lungpacer Medical，Inc.自2021年6月起，AES Clean Technology，Inc.自2019年3月起，以及一家非营利性私营基金会LOR基金会自2015年1月起。Donohue先生获得了Widener大学的工商管理硕士学位和西切斯特大学的经济学理学学士学位，他是一名前注册会计师。
Robert Donohue has served as a director of Centinel since December 2017 in his capacity as a representative of AW Alpha Capital LLC on Centinel's board. Mr. Donohue has served as a manager of AW Alpha Capital LLC, an affiliate of WJFS, Inc., a private investment group, since November of 2017. Since January 2014, Mr. Donohue has served as Chief Executive Officer and Chief Financial Officer of WJFS, Inc. From 1998 through June of 2012, Mr. Donohue held the position of Chief Financial Officer of Synthes, Inc., a formerly public medical device manufacturer listed on the SIX Swiss Exchange. In addition, from 1997 to June of 2012, Mr. Donohue held the position of President, Synthes Canada, Ltd., a subsidiary of Synthes, Inc. Mr. Donohue started with Synthes (USA) in 1990 as the Corporate Controller and shortly thereafter was promoted to VP of Finance. Prior to joining Synthes, he served in several financial positions, including corporate controller and plant controller with several major U.S. corporations. In addition to his board seat at Centinel, Mr. Donohue also has served on the board of two privately held companies in, or serving, the life sciences industry, Lungpacer Medical, Inc. since June 2021 and AES Clean Technology, Inc. since March 2019, and a non profit private foundation, the LOR Foundation since January 2015. Mr. Donohue received an M.B.A. from Widener University and a B.Sc. in Economics from West Chester University, and he is a former Certified Public Accountant. - Robert Donohue自2017年12月起担任Centinel董事，担任Centinel董事会AW Alpha Capital LLC代表。Donohue先生自2017年11月起担任私人投资集团WJFS，Inc.的关联公司AW Alpha Capital LLC的经理。自2014年1月起，Donohue先生担任WJFS，Inc.的首席执行官兼首席财务官。从1998年至2012年6月，Donohue先生担任Synthes，Inc.的首席财务官职务，该公司以前是一家在瑞士六家交易所上市的公立医疗器械制造商。此外，从1997年到2012年6月，Donohue先生担任Synthes，Inc.的子公司Synthes Canada，Ltd.的总裁职务。Donohue先生于1990年在Synthes（USA）开始担任公司财务总监，此后不久晋升为财务副总裁。在加入Synthes之前，他曾在多个财务岗位任职，包括在几家美国大公司担任公司财务总监和工厂总监。除了在Centinel的董事会席位外，Donohue先生还曾在生命科学行业的两家私营公司的董事会任职，或服务于生命科学行业，Lungpacer Medical，Inc.自2021年6月起，AES Clean Technology，Inc.自2019年3月起，以及一家非营利性私营基金会LOR基金会自2015年1月起。Donohue先生获得了Widener大学的工商管理硕士学位和西切斯特大学的经济学理学学士学位，他是一名前注册会计师。
- Robert Donohue has served as a director of Centinel since December 2017 in his capacity as a representative of AW Alpha Capital LLC on Centinel's board. Mr. Donohue has served as a manager of AW Alpha Capital LLC, an affiliate of WJFS, Inc., a private investment group, since November of 2017. Since January 2014, Mr. Donohue has served as Chief Executive Officer and Chief Financial Officer of WJFS, Inc. From 1998 through June of 2012, Mr. Donohue held the position of Chief Financial Officer of Synthes, Inc., a formerly public medical device manufacturer listed on the SIX Swiss Exchange. In addition, from 1997 to June of 2012, Mr. Donohue held the position of President, Synthes Canada, Ltd., a subsidiary of Synthes, Inc. Mr. Donohue started with Synthes (USA) in 1990 as the Corporate Controller and shortly thereafter was promoted to VP of Finance. Prior to joining Synthes, he served in several financial positions, including corporate controller and plant controller with several major U.S. corporations. In addition to his board seat at Centinel, Mr. Donohue also has served on the board of two privately held companies in, or serving, the life sciences industry, Lungpacer Medical, Inc. since June 2021 and AES Clean Technology, Inc. since March 2019, and a non profit private foundation, the LOR Foundation since January 2015. Mr. Donohue received an M.B.A. from Widener University and a B.Sc. in Economics from West Chester University, and he is a former Certified Public Accountant.
- Craig Greener
-
Craig Greener自2023年4月起以AW Alpha Capital LLC代表的身份担任Centinel董事。Greener先生自2015年4月起担任WJFS，Inc.的收购总监。在加入WJFS，Inc.之前，Greener先生于2008年5月至2015年4月期间任职于强生 — DePuy Synthes，专注于并购业务。Greener先生获得了詹姆斯麦迪逊大学的金融学学士学位，并自2000年9月起担任CFA特许持有人。格林纳有资格在Centinel Spine Holdco，Inc.的董事会任职，因为他有投资和金融经验，并且对Centinel Spine Holdco，Inc.的业务了如指掌。
Craig Greener has served as a director of Centinel since April 2023 in his capacity as a representative of AW Alpha Capital LLC. Mr. Greener has served as Director of Acquisitions for WJFS, Inc. since April 2015. Prior to joining WJFS, Inc., Mr. Greener worked for Johnson & Johnson—DePuy Synthes from May 2008 to April 2015 focusing on mergers and acquisitions. Mr. Greener received a B.B.A. in Finance from James Madison University and has been a CFA Charterholder since September 2000. - Craig Greener自2023年4月起以AW Alpha Capital LLC代表的身份担任Centinel董事。Greener先生自2015年4月起担任WJFS，Inc.的收购总监。在加入WJFS，Inc.之前，Greener先生于2008年5月至2015年4月期间任职于强生 — DePuy Synthes，专注于并购业务。Greener先生获得了詹姆斯麦迪逊大学的金融学学士学位，并自2000年9月起担任CFA特许持有人。格林纳有资格在Centinel Spine Holdco，Inc.的董事会任职，因为他有投资和金融经验，并且对Centinel Spine Holdco，Inc.的业务了如指掌。
- Craig Greener has served as a director of Centinel since April 2023 in his capacity as a representative of AW Alpha Capital LLC. Mr. Greener has served as Director of Acquisitions for WJFS, Inc. since April 2015. Prior to joining WJFS, Inc., Mr. Greener worked for Johnson & Johnson—DePuy Synthes from May 2008 to April 2015 focusing on mergers and acquisitions. Mr. Greener received a B.B.A. in Finance from James Madison University and has been a CFA Charterholder since September 2000.
- Dirk Kuyper
-
Dirk Kuyper，2008年1月起，他担任公司和Alphatec Spine的董事。2012年2月起，他担任全球商业运营总裁。2007年6月至2012年2月，他担任公司和Alphatec Spine的总裁和首席执行官。2004至2007年，他担任Aesculap, Inc的总裁，该公司制造并销售外科植入物和工具，包括脊椎手术使用的植入物和工具。2001至2004年，他担任Aesculap Inc.的执行副总裁和首席运营官。1998至2001年，他担任Aesculap Inc.的市场营销执行副总裁。1990至1998年，他在Aesculap Inc.担任多职，责任越来越重。 他曾在美国陆军服役4年，达到上尉等级。
Dirk Kuyper has served as a director of Centinel since December 2018. Mr. Kuyper has been the owner, President and CEO of Precision Machinists Company, Inc, an OEM parts manufacturer for medical, semiconductor and aerospace industries, since December 2014. In addition, from January 2020 until April 2024, Mr. Kuyper served as Managing Director of Joline Medical LLC, a medical device company focused on pain management. From April 2013 until September 2014, Mr. Kuyper served as President and CEO of Illuminoss Medical, Inc., a privately-held medical device company specializing in minimally invasive, patient customized orthopedic implants for the treatment of bone fractures. Prior to joining Illuminoss in April 2013, from August 2012 until April 2013 Mr. Kuyper served as a Partner at Strategic Medical Consulting Group, LLC, providing strategic consulting and advice for a number of medical device companies including Benvenue Medical, Inc., a developer of MIS lumbar fusion systems. From June 2007 to August 2012, Mr. Kuyper served as the President and CEO, and as a member of the board of directors, of Alphatec Holdings, Inc. (Nasdaq: ATEC), a medical technology company focused on the design, development, and advancement of technology for better surgical treatment of spinal disorders. Prior to his work for Alphatec, from June 1990 to June 2007 Mr. Kuyper served in several executive capacities, including as President and as Executive Vice President and Chief Operating Officer, for Aesculap, Inc., a member of the B Braun group of companies and a provider of surgical tools. From July 2013 until August 2019, Mr. Kuyper served as an independent director of Conmed Corporation, (NYSE: CNMD), during which time he served as chairman of the compensation committee from July 2013 until August 2019 and as a member of nominating and governance committee from February 2016 until August 2019. Mr. Kuyper served in the US Army where he achieved the rank of Captain. Mr. Kuyper received a B.S. in Biology from the University of Miami. - Dirk Kuyper，2008年1月起，他担任公司和Alphatec Spine的董事。2012年2月起，他担任全球商业运营总裁。2007年6月至2012年2月，他担任公司和Alphatec Spine的总裁和首席执行官。2004至2007年，他担任Aesculap, Inc的总裁，该公司制造并销售外科植入物和工具，包括脊椎手术使用的植入物和工具。2001至2004年，他担任Aesculap Inc.的执行副总裁和首席运营官。1998至2001年，他担任Aesculap Inc.的市场营销执行副总裁。1990至1998年，他在Aesculap Inc.担任多职，责任越来越重。 他曾在美国陆军服役4年，达到上尉等级。
- Dirk Kuyper has served as a director of Centinel since December 2018. Mr. Kuyper has been the owner, President and CEO of Precision Machinists Company, Inc, an OEM parts manufacturer for medical, semiconductor and aerospace industries, since December 2014. In addition, from January 2020 until April 2024, Mr. Kuyper served as Managing Director of Joline Medical LLC, a medical device company focused on pain management. From April 2013 until September 2014, Mr. Kuyper served as President and CEO of Illuminoss Medical, Inc., a privately-held medical device company specializing in minimally invasive, patient customized orthopedic implants for the treatment of bone fractures. Prior to joining Illuminoss in April 2013, from August 2012 until April 2013 Mr. Kuyper served as a Partner at Strategic Medical Consulting Group, LLC, providing strategic consulting and advice for a number of medical device companies including Benvenue Medical, Inc., a developer of MIS lumbar fusion systems. From June 2007 to August 2012, Mr. Kuyper served as the President and CEO, and as a member of the board of directors, of Alphatec Holdings, Inc. (Nasdaq: ATEC), a medical technology company focused on the design, development, and advancement of technology for better surgical treatment of spinal disorders. Prior to his work for Alphatec, from June 1990 to June 2007 Mr. Kuyper served in several executive capacities, including as President and as Executive Vice President and Chief Operating Officer, for Aesculap, Inc., a member of the B Braun group of companies and a provider of surgical tools. From July 2013 until August 2019, Mr. Kuyper served as an independent director of Conmed Corporation, (NYSE: CNMD), during which time he served as chairman of the compensation committee from July 2013 until August 2019 and as a member of nominating and governance committee from February 2016 until August 2019. Mr. Kuyper served in the US Army where he achieved the rank of Captain. Mr. Kuyper received a B.S. in Biology from the University of Miami.
高管简历
中英对照 | 中文 | 英文- Peter Ringwood
Peter Ringwood自2022年1月起担任Centinel运营副总裁。在加入Centinel之前，Ringwood先生在2020年12月至2021年12月期间担任Conventus Flower Orthopedics的运营副总裁，Conventus Flower Orthopedics是一家专注于骨科手术预包装手术解决方案的医疗设备制造商。从2002年4月至2020年12月，Ringwood先生担任运营总监，后来担任B & G Manufacturing的总经理，B & G Manufacturing是一家为医疗、航空航天、能源和国防等关键行业提供精密机械加工零件的合同制造商。Ringwood先生拥有马里兰洛约拉大学的工商管理硕士学位和克拉克森大学的工程与商业学士学位。
Peter Ringwood has served as Centinel's Vice President, Operations since January 2022. Prior to joining Centinel, Mr. Ringwood served as Vice President of Operations for Conventus Flower Orthopedics, a medical device manufacturer specializing in prepackaged surgical solutions for orthopedic procedures, from December 2020 to December 2021. From April 2002 to December 2020, Mr. Ringwood served as Director of Operations and later as General Manager for B&G Manufacturing, a contract manufacturer of precision machined parts for critical industries including medical, aerospace, energy and defense. Mr. Ringwood holds an M.B.A. from Loyola University Maryland and a B.S. in Engineering & Business from Clarkson University.- Peter Ringwood自2022年1月起担任Centinel运营副总裁。在加入Centinel之前，Ringwood先生在2020年12月至2021年12月期间担任Conventus Flower Orthopedics的运营副总裁，Conventus Flower Orthopedics是一家专注于骨科手术预包装手术解决方案的医疗设备制造商。从2002年4月至2020年12月，Ringwood先生担任运营总监，后来担任B & G Manufacturing的总经理，B & G Manufacturing是一家为医疗、航空航天、能源和国防等关键行业提供精密机械加工零件的合同制造商。Ringwood先生拥有马里兰洛约拉大学的工商管理硕士学位和克拉克森大学的工程与商业学士学位。
- Peter Ringwood has served as Centinel's Vice President, Operations since January 2022. Prior to joining Centinel, Mr. Ringwood served as Vice President of Operations for Conventus Flower Orthopedics, a medical device manufacturer specializing in prepackaged surgical solutions for orthopedic procedures, from December 2020 to December 2021. From April 2002 to December 2020, Mr. Ringwood served as Director of Operations and later as General Manager for B&G Manufacturing, a contract manufacturer of precision machined parts for critical industries including medical, aerospace, energy and defense. Mr. Ringwood holds an M.B.A. from Loyola University Maryland and a B.S. in Engineering & Business from Clarkson University.
- Jason Hoffman
Jason Hoffman自2023年1月起担任Centinel业务和市场开发副总裁。Hoffman先生于2017年8月加入Centinel，担任销售副总裁。在加入Centinel之前，Hoffman先生于2015年7月至2017年6月担任新兴脊柱公司Providence Medical Technology，Inc.的全球销售副总裁。从2010年3月到2014年9月，Hoffman先生担任全球医疗技术公司ArjoHuntleigh的治疗支持系统美国销售副总裁，在Kinetic Concepts Inc.（被ArjoHuntleigh收购之前）任职两年，随后在ArjoHuntleigh（被Kinetic Concepts Inc.收购之后）任职两年，整合多元化的伤口护理和患者处理商业销售团队。从1997年到2010年3月，Hoffman先生曾在不同职位任职，包括担任高级区域业务总监，在强生公司的各个生物技术部门任职。具体来说，他曾在Ortho Biotech和CentoCor部门任职，担任销售、销售培训、市场营销以及从经理到高级总监职位的责任不断增加的销售领导职务。霍夫曼先生获得了北卡罗来纳立大学政治学学士学位。
Jason Hoffman has served as Vice President, Business and Market Development of Centinel since January 2023. Mr. Hoffman joined Centinel as Vice President of Sales in August 2017. Prior to joining Centinel, Mr. Hoffman served as Vice President, Global Sales for Providence Medical Technology, Inc., an emerging spine company, from July 2015 to June 2017. From March 2010 to September 2014, Mr. Hoffman served as Vice President of US Sales, Therapeutic Support Systems for ArjoHuntleigh, a global medical technology company, working two years in this position with Kinetic Concepts Inc. (prior to its acquisition by ArjoHuntleigh) and then two years with ArjoHuntleigh (after its acquisition of Kinetic Concepts Inc.), to integrate a diverse wound care and patient handling commercial sales team. From 1997 to March 2010, Mr. Hoffman served in different positions, including as Senior Regional Business Director, with Johnson & Johnson, Inc. in various biotechnology divisions. Specifically, he worked in both Ortho Biotech and Centocor divisions, in sales, sales training, marketing, as well as sales leadership roles of increasing responsibility from Manager through Senior Director positions. Mr. Hoffman received a B.A. in Political Science from North Carolina State University.- Jason Hoffman自2023年1月起担任Centinel业务和市场开发副总裁。Hoffman先生于2017年8月加入Centinel，担任销售副总裁。在加入Centinel之前，Hoffman先生于2015年7月至2017年6月担任新兴脊柱公司Providence Medical Technology，Inc.的全球销售副总裁。从2010年3月到2014年9月，Hoffman先生担任全球医疗技术公司ArjoHuntleigh的治疗支持系统美国销售副总裁，在Kinetic Concepts Inc.（被ArjoHuntleigh收购之前）任职两年，随后在ArjoHuntleigh（被Kinetic Concepts Inc.收购之后）任职两年，整合多元化的伤口护理和患者处理商业销售团队。从1997年到2010年3月，Hoffman先生曾在不同职位任职，包括担任高级区域业务总监，在强生公司的各个生物技术部门任职。具体来说，他曾在Ortho Biotech和CentoCor部门任职，担任销售、销售培训、市场营销以及从经理到高级总监职位的责任不断增加的销售领导职务。霍夫曼先生获得了北卡罗来纳立大学政治学学士学位。
- Jason Hoffman has served as Vice President, Business and Market Development of Centinel since January 2023. Mr. Hoffman joined Centinel as Vice President of Sales in August 2017. Prior to joining Centinel, Mr. Hoffman served as Vice President, Global Sales for Providence Medical Technology, Inc., an emerging spine company, from July 2015 to June 2017. From March 2010 to September 2014, Mr. Hoffman served as Vice President of US Sales, Therapeutic Support Systems for ArjoHuntleigh, a global medical technology company, working two years in this position with Kinetic Concepts Inc. (prior to its acquisition by ArjoHuntleigh) and then two years with ArjoHuntleigh (after its acquisition of Kinetic Concepts Inc.), to integrate a diverse wound care and patient handling commercial sales team. From 1997 to March 2010, Mr. Hoffman served in different positions, including as Senior Regional Business Director, with Johnson & Johnson, Inc. in various biotechnology divisions. Specifically, he worked in both Ortho Biotech and Centocor divisions, in sales, sales training, marketing, as well as sales leadership roles of increasing responsibility from Manager through Senior Director positions. Mr. Hoffman received a B.A. in Political Science from North Carolina State University.
- James Kuras
James Kuras自2021年2月起担任Centinel的临床、监管和质量事务副总裁。2017年8月至2020年1月，Kuras先生担任Centinel临床运营副总裁。在2021年2月重新加入Centinel之前，Kuras先生于2020年1月至2021年1月在ACell公司担任研发和临床事务副总裁，该公司专注于使用源自猪膀胱的新型细胞外基质结构进行伤口修复和前壁重建。从2015年5月到2017年7月，Kuras先生在Innovative Medical Equipment LLC和Mercury BioMed LLC担任产品开发副总裁，这两家公司是为家庭医疗保健和围手术期临床市场开发热和冷疗法的初创公司。从2001年3月到2014年11月，Kuras先生是AxioMed Spine Corp的首席运营官和创始人，该公司专注于开发和研究下一代颈椎和木材全盘置换技术。Kuras先生拥有扬斯敦州立大学电气工程技术应用科学学士学位。
James Kuras has served as Centinel's Vice President, Clinical, Regulatory and Quality Affairs since February 2021. From August 2017 to January 2020, Mr. Kuras served as Vice President, Clinical Operations at Centinel. Prior to rejoining Centinel in February 2021, Mr. Kuras was the Vice President of R&D and Clinical Affairs at ACell, Inc., a company focused on wound repair and anterior wall reconstruction using a novel extracellular matrix structure derived from porcine bladders, from January 2020 to January 2021. From May 2015 to July 2017, Mr. Kuras served as Vice President of Product Development at both Innovative Medical Equipment LLC and Mercury BioMed LLC, which are start up companies developing heat and cool therapies for the home healthcare and perioperative clinical markets. From March 2001 to November 2014, Mr. Kuras was the Chief Operating Officer and founder of AxioMed Spine Corp, a company focused on the development and study of next generation cervical and lumber total disc replacement technologies. Mr. Kuras holds a B.S. in Applied Science in Electrical Engineering Technology from Youngstown State University.- James Kuras自2021年2月起担任Centinel的临床、监管和质量事务副总裁。2017年8月至2020年1月，Kuras先生担任Centinel临床运营副总裁。在2021年2月重新加入Centinel之前，Kuras先生于2020年1月至2021年1月在ACell公司担任研发和临床事务副总裁，该公司专注于使用源自猪膀胱的新型细胞外基质结构进行伤口修复和前壁重建。从2015年5月到2017年7月，Kuras先生在Innovative Medical Equipment LLC和Mercury BioMed LLC担任产品开发副总裁，这两家公司是为家庭医疗保健和围手术期临床市场开发热和冷疗法的初创公司。从2001年3月到2014年11月，Kuras先生是AxioMed Spine Corp的首席运营官和创始人，该公司专注于开发和研究下一代颈椎和木材全盘置换技术。Kuras先生拥有扬斯敦州立大学电气工程技术应用科学学士学位。
- James Kuras has served as Centinel's Vice President, Clinical, Regulatory and Quality Affairs since February 2021. From August 2017 to January 2020, Mr. Kuras served as Vice President, Clinical Operations at Centinel. Prior to rejoining Centinel in February 2021, Mr. Kuras was the Vice President of R&D and Clinical Affairs at ACell, Inc., a company focused on wound repair and anterior wall reconstruction using a novel extracellular matrix structure derived from porcine bladders, from January 2020 to January 2021. From May 2015 to July 2017, Mr. Kuras served as Vice President of Product Development at both Innovative Medical Equipment LLC and Mercury BioMed LLC, which are start up companies developing heat and cool therapies for the home healthcare and perioperative clinical markets. From March 2001 to November 2014, Mr. Kuras was the Chief Operating Officer and founder of AxioMed Spine Corp, a company focused on the development and study of next generation cervical and lumber total disc replacement technologies. Mr. Kuras holds a B.S. in Applied Science in Electrical Engineering Technology from Youngstown State University.
- Varun Gandhi
Varun Gandhi自2020年8月起担任Centinel公司首席财务官。Gandhi先生于2014年10月至2019年6月担任企业财务和战略规划高级副总裁，并于2019年6月至2020年12月担任Centinel国际总经理。2005年9月至2005年12月，Gandhi先生在Viscogliosi Brothers，LLC担任分析师，该公司是一家专注于神经肌肉骨骼行业（“VB”）的单一家族办公室。2006年1月至2014年8月，甘地先生在Small Bone Innovations，Inc.担任公司财务和战略规划副总裁，该公司是一家专注于四肢疾病的医疗设备公司，已被史赛克公司和Centinel收购。在VB任职期间，从2014年10月到2019年9月，甘地先生是Centinel的高级领导层成员。从2006年1月到2014年9月，甘地先生大部分时间都在VB为Small Bone Innovations，Inc.提供服务，他在那里担任过多个职位，最近担任战略规划和公司财务副总裁。甘地先生在新泽西州立大学罗格斯大学获得生物医学工程和经济学学士学位。
Varun Gandhi has served as the Chief Financial Officer of Centinel since August 2020. Mr. Gandhi was Senior Vice President of Corporate Finance and Strategic Planning from October 2014 until June 2019 and General Manager, International at Centinel from June 2019 until December 2020. From September 2005 to December 2005, Mr. Gandhi worked as an analyst at Viscogliosi Brothers, LLC a single family office focused on the neuro musculoskeletal industry ("VB"). From January 2006 to August 2014, Mr. Gandhi served as Vice President of Corporate Finance and Strategic Planning at Small Bone Innovations, Inc., an extremities focused medical device company acquired by Stryker Corporation, and Centinel. While at VB, from October 2014 to September 2019, Mr. Gandhi was a member of Centinel's senior leadership, and from January 2006 to September 2014, Mr. Gandhi spent the majority of his time at VB providing services to Small Bone Innovations, Inc., where he held various positions, most recently as Vice President of Strategic Planning and Corporate Finance. Mr. Gandhi received a B.S. in Biomedical Engineering and Economics from Rutgers, The State University of New Jersey.- Varun Gandhi自2020年8月起担任Centinel公司首席财务官。Gandhi先生于2014年10月至2019年6月担任企业财务和战略规划高级副总裁，并于2019年6月至2020年12月担任Centinel国际总经理。2005年9月至2005年12月，Gandhi先生在Viscogliosi Brothers，LLC担任分析师，该公司是一家专注于神经肌肉骨骼行业（“VB”）的单一家族办公室。2006年1月至2014年8月，甘地先生在Small Bone Innovations，Inc.担任公司财务和战略规划副总裁，该公司是一家专注于四肢疾病的医疗设备公司，已被史赛克公司和Centinel收购。在VB任职期间，从2014年10月到2019年9月，甘地先生是Centinel的高级领导层成员。从2006年1月到2014年9月，甘地先生大部分时间都在VB为Small Bone Innovations，Inc.提供服务，他在那里担任过多个职位，最近担任战略规划和公司财务副总裁。甘地先生在新泽西州立大学罗格斯大学获得生物医学工程和经济学学士学位。
- Varun Gandhi has served as the Chief Financial Officer of Centinel since August 2020. Mr. Gandhi was Senior Vice President of Corporate Finance and Strategic Planning from October 2014 until June 2019 and General Manager, International at Centinel from June 2019 until December 2020. From September 2005 to December 2005, Mr. Gandhi worked as an analyst at Viscogliosi Brothers, LLC a single family office focused on the neuro musculoskeletal industry ("VB"). From January 2006 to August 2014, Mr. Gandhi served as Vice President of Corporate Finance and Strategic Planning at Small Bone Innovations, Inc., an extremities focused medical device company acquired by Stryker Corporation, and Centinel. While at VB, from October 2014 to September 2019, Mr. Gandhi was a member of Centinel's senior leadership, and from January 2006 to September 2014, Mr. Gandhi spent the majority of his time at VB providing services to Small Bone Innovations, Inc., where he held various positions, most recently as Vice President of Strategic Planning and Corporate Finance. Mr. Gandhi received a B.S. in Biomedical Engineering and Economics from Rutgers, The State University of New Jersey.
- Fadel Ghossein
Fadel Ghossein自2021年1月起担任Centinel国际副总裁。Ghossein先生负责Centinel国际业务的各个方面。在加入Centinel之前，Ghossein先生曾于2017年2月至2021年1月担任私营医疗器械公司Spineart SA的西欧和北欧分部总监。在此之前，他在强生 — Depuy Synthes担任逐渐升级的职务，包括2015年9月至2017年2月的Spine事业部经理；2012年11月至2015年9月的区域销售经理；2012年6月至2013年1月的Merger Integration经理；2010年11月至2012年11月的Synthes Spine产品经理；2007年4月至2012年11月的销售代表。在此之前，他曾于2003年4月至2007年4月担任柯达医疗成像系统（现为Carestream Health，Inc.的一部分）的销售主管。Ghossein先生获得了Luiss商学院的工商管理硕士学位，并获得了蓝色海岸大学、Henri Poincar é大学（南希一世）和Victor Segalen大学（波尔多二世）的学位。
Fadel Ghossein has served as Vice President International of Centinel since January 2021. Mr. Ghossein is responsible for all aspects of Centinel's international business. Prior to joining Centinel, Mr. Ghossein served as the Director of Western & North Europe division of Spineart SA, a privately held medical device company, from February 2017 to January 2021. Prior to that, he held escalating roles at Johnson & Johnson—DePuy Synthes, including Business Unit Manager of Spine from September 2015 to February 2017; Regional Sales Manager from November 2012 to September 2015; Merger Integration Manager from June 2012 to January 2013; Product Manager for Synthes Spine from November 2010 to November 2012; and Sales Representative from April 2007 to November 2012. Prior to that, he served as Sales Executive for Kodak Medical Imaging Systems (now part of Carestream Health, Inc.) from April 2003 to April 2007. Mr. Ghossein received an M.B.A. from Luiss Business School, and degrees from the Université Cte d'Azur, Université Henri Poincaré (Nancy I), and Université Victor Segalen (Bordeaux II).- Fadel Ghossein自2021年1月起担任Centinel国际副总裁。Ghossein先生负责Centinel国际业务的各个方面。在加入Centinel之前，Ghossein先生曾于2017年2月至2021年1月担任私营医疗器械公司Spineart SA的西欧和北欧分部总监。在此之前，他在强生 — Depuy Synthes担任逐渐升级的职务，包括2015年9月至2017年2月的Spine事业部经理；2012年11月至2015年9月的区域销售经理；2012年6月至2013年1月的Merger Integration经理；2010年11月至2012年11月的Synthes Spine产品经理；2007年4月至2012年11月的销售代表。在此之前，他曾于2003年4月至2007年4月担任柯达医疗成像系统（现为Carestream Health，Inc.的一部分）的销售主管。Ghossein先生获得了Luiss商学院的工商管理硕士学位，并获得了蓝色海岸大学、Henri Poincar é大学（南希一世）和Victor Segalen大学（波尔多二世）的学位。
- Fadel Ghossein has served as Vice President International of Centinel since January 2021. Mr. Ghossein is responsible for all aspects of Centinel's international business. Prior to joining Centinel, Mr. Ghossein served as the Director of Western & North Europe division of Spineart SA, a privately held medical device company, from February 2017 to January 2021. Prior to that, he held escalating roles at Johnson & Johnson—DePuy Synthes, including Business Unit Manager of Spine from September 2015 to February 2017; Regional Sales Manager from November 2012 to September 2015; Merger Integration Manager from June 2012 to January 2013; Product Manager for Synthes Spine from November 2010 to November 2012; and Sales Representative from April 2007 to November 2012. Prior to that, he served as Sales Executive for Kodak Medical Imaging Systems (now part of Carestream Health, Inc.) from April 2003 to April 2007. Mr. Ghossein received an M.B.A. from Luiss Business School, and degrees from the Université Cte d'Azur, Université Henri Poincaré (Nancy I), and Université Victor Segalen (Bordeaux II).
- Steven Murray
Steven Murray自2020年3月起担任Centinel首席执行官。在加入Centinel之前，Murray先生于2018年2月至2019年4月担任强生（NYSE：JNJ）高级灭菌产品部门的全球总裁；于2014年7月至2018年1月担任强生心脏病学和临床诊断业务的副总裁兼总经理；于2012年7月至2014年1月担任强生 — Depuy Synthes Neuro的Neuro全球总裁，该公司是强生业务，致力于面部、颅脑创伤和病理。在此之前，Murray先生于2010年6月至2012年6月担任Synthes Spine的总裁，该公司是一家脊柱融合和运动保持技术公司，现隶属于强生。Murray先生还曾在2000年4月至2010年5月期间担任Synthes Craniomaxillofacial的总裁，该公司是一家创伤和重建公司，现隶属于强生。自2016年以来，默里先生一直担任非营利组织世界颅面基金会的董事。默里先生在达特茅斯学院的阿莫斯·塔克工商管理学院获得工商管理硕士学位，在俄亥俄州牛津的迈阿密大学获得经济学学士学位。
Steven Murray has served as the Chief Executive Officer of Centinel since March 2020. Prior to joining Centinel, Mr. Murray was Worldwide President of Advanced Sterilization Products division of Johnson & Johnson, Inc. (NYSE: JNJ) from February 2018 to April 2019; Vice President & General Manager of Johnson & Johnson cardiology and clinical diagnostics businesses from July 2014 to January 2018; and Worldwide President of Neuro of Johnson & Johnson—DePuy Synthes Neuro, a Johnson & Johnson business addressing facial, cranial, and brain trauma & pathologies, from July 2012 to June 2014. Prior to that, Mr. Murray served as President of Synthes Spine, a spine fusion and motion preservation technologies company and now part of Johnson & Johnson, from June 2010 to June 2012. Mr. Murray also served as President of Synthes Craniomaxillofacial, a trauma and reconstruction company and now part of Johnson & Johnson, from April 2000 to May 2010. Mr. Murray has served as a director of the non profit organization, World Craniofacial Foundation since 2016. Mr. Murray received an M.B.A. from the Amos Tuck School of Business Administration at Dartmouth College, and a B.A. in Economics from Miami University, Oxford, Ohio.- Steven Murray自2020年3月起担任Centinel首席执行官。在加入Centinel之前，Murray先生于2018年2月至2019年4月担任强生（NYSE：JNJ）高级灭菌产品部门的全球总裁；于2014年7月至2018年1月担任强生心脏病学和临床诊断业务的副总裁兼总经理；于2012年7月至2014年1月担任强生 — Depuy Synthes Neuro的Neuro全球总裁，该公司是强生业务，致力于面部、颅脑创伤和病理。在此之前，Murray先生于2010年6月至2012年6月担任Synthes Spine的总裁，该公司是一家脊柱融合和运动保持技术公司，现隶属于强生。Murray先生还曾在2000年4月至2010年5月期间担任Synthes Craniomaxillofacial的总裁，该公司是一家创伤和重建公司，现隶属于强生。自2016年以来，默里先生一直担任非营利组织世界颅面基金会的董事。默里先生在达特茅斯学院的阿莫斯·塔克工商管理学院获得工商管理硕士学位，在俄亥俄州牛津的迈阿密大学获得经济学学士学位。
- Steven Murray has served as the Chief Executive Officer of Centinel since March 2020. Prior to joining Centinel, Mr. Murray was Worldwide President of Advanced Sterilization Products division of Johnson & Johnson, Inc. (NYSE: JNJ) from February 2018 to April 2019; Vice President & General Manager of Johnson & Johnson cardiology and clinical diagnostics businesses from July 2014 to January 2018; and Worldwide President of Neuro of Johnson & Johnson—DePuy Synthes Neuro, a Johnson & Johnson business addressing facial, cranial, and brain trauma & pathologies, from July 2012 to June 2014. Prior to that, Mr. Murray served as President of Synthes Spine, a spine fusion and motion preservation technologies company and now part of Johnson & Johnson, from June 2010 to June 2012. Mr. Murray also served as President of Synthes Craniomaxillofacial, a trauma and reconstruction company and now part of Johnson & Johnson, from April 2000 to May 2010. Mr. Murray has served as a director of the non profit organization, World Craniofacial Foundation since 2016. Mr. Murray received an M.B.A. from the Amos Tuck School of Business Administration at Dartmouth College, and a B.A. in Economics from Miami University, Oxford, Ohio.
- Steven Sanderson
自2019年3月起，Steven Sanderson担任Centinel营销和产品开发副总裁。Sanderson先生于2018年1月加入Centinel，担任营销副总裁，负责领导所有全球战略和运营营销及产品开发活动。在加入Centinel之前，Sanderson先生曾于2007年6月至2017年4月在全球医疗技术公司Integra Lifesciences担任过不同职务，最近担任骨科和骨科部门的高级营销总监。在此之前，他曾于1999年9月至2007年6月在美洲奥林巴斯公司担任多个领导职务。桑德森先生获得了天普大学的工商管理硕士学位、俄亥俄州立大学的硕士学位和圣母大学的学士学位。
Steven Sanderson has served as Centinel's Vice President of Marketing and Product Development since March 2019. Mr. Sanderson, who joined Centinel in January 2018 as Vice President of Marketing, is responsible for leading all global strategic and operational marketing and product development activities. Prior to joining Centinel, Mr. Sanderson served in different positions with Integra Lifesciences, a global medical technology company, from June 2007 to April 2017, most recently as Senior Director of Marketing in the Orthopedics & Orthobiologics division. Prior to that, he held various leadership positions with Olympus Corporation of the Americas from September 1999 through June 2007. Mr. Sanderson received an M.B.A. from Temple University, a M.S. from The Ohio State University, and a B.S. from the University of Notre Dame.- 自2019年3月起，Steven Sanderson担任Centinel营销和产品开发副总裁。Sanderson先生于2018年1月加入Centinel，担任营销副总裁，负责领导所有全球战略和运营营销及产品开发活动。在加入Centinel之前，Sanderson先生曾于2007年6月至2017年4月在全球医疗技术公司Integra Lifesciences担任过不同职务，最近担任骨科和骨科部门的高级营销总监。在此之前，他曾于1999年9月至2007年6月在美洲奥林巴斯公司担任多个领导职务。桑德森先生获得了天普大学的工商管理硕士学位、俄亥俄州立大学的硕士学位和圣母大学的学士学位。
- Steven Sanderson has served as Centinel's Vice President of Marketing and Product Development since March 2019. Mr. Sanderson, who joined Centinel in January 2018 as Vice President of Marketing, is responsible for leading all global strategic and operational marketing and product development activities. Prior to joining Centinel, Mr. Sanderson served in different positions with Integra Lifesciences, a global medical technology company, from June 2007 to April 2017, most recently as Senior Director of Marketing in the Orthopedics & Orthobiologics division. Prior to that, he held various leadership positions with Olympus Corporation of the Americas from September 1999 through June 2007. Mr. Sanderson received an M.B.A. from Temple University, a M.S. from The Ohio State University, and a B.S. from the University of Notre Dame.
- Jeanina Bradley
Jeanina Bradley自2026年5月起担任Centinel美国销售副总裁。Bradley女士于2019年7月加入Centinel，担任区域销售经理，随后于2021年12月晋升为山区/中央区域副总裁。在加入Centinel之前，Bradley女士曾于2014年8月至2018年12月担任美国南部多州脊柱和骨科分销商Align Alternatives的脊柱和分销商合作伙伴副总裁。2004年至2014年，Bradley女士曾担任不同的医疗设备和市场开发职位，包括2013年8月至2014年8月担任北德克萨斯州卫理公会卫生系统穆迪脑和脊柱研究所的发展总监，2012年3月至2013年7月担任NuVasive，Inc.的脊柱专家，以及2004年10月至2012年3月担任波士顿科学国际有限公司的销售助理和区域经理。她曾在销售、销售培训、市场等领域工作，并担任过责任不断增加、范围不断扩大的销售领导角色。布拉德利女士获得了得克萨斯大学达拉斯分校的表演艺术学士学位。
Jeanina Bradley has served as Centinel's Vice President, U.S. Sales since May 2026. Ms. Bradley joined Centinel in July 2019 as a Regional Sales Manager and was subsequently promoted to Area Vice President, Mountain/Central in December 2021. Prior to joining Centinel, Ms. Bradley served as Vice President of Spine and Distributor Partner for Align Alternatives, a multistate spine and orthopedic distributor in the southern United States, from August 2014 to December 2018. From 2004 to 2014, Ms. Bradley served in different medical device and market development positions, including as Director of Development for Methodist Health System Moody Brain and Spine Institute in North Texas from August 2013 through August 2014, as a Spine Specialist for NuVasive, Inc. from March 2012 through July 2013, and as a Sales Associate and Territory Manager for Boston Scientific Corporation from October 2004 through March 2012. She has worked in sales, sales training, and marketing, as well as sales leadership roles of increasing responsibility and scope. Ms. Bradley received a B.A. in Performing Arts from The University of Texas at Dallas.- Jeanina Bradley自2026年5月起担任Centinel美国销售副总裁。Bradley女士于2019年7月加入Centinel，担任区域销售经理，随后于2021年12月晋升为山区/中央区域副总裁。在加入Centinel之前，Bradley女士曾于2014年8月至2018年12月担任美国南部多州脊柱和骨科分销商Align Alternatives的脊柱和分销商合作伙伴副总裁。2004年至2014年，Bradley女士曾担任不同的医疗设备和市场开发职位，包括2013年8月至2014年8月担任北德克萨斯州卫理公会卫生系统穆迪脑和脊柱研究所的发展总监，2012年3月至2013年7月担任NuVasive，Inc.的脊柱专家，以及2004年10月至2012年3月担任波士顿科学国际有限公司的销售助理和区域经理。她曾在销售、销售培训、市场等领域工作，并担任过责任不断增加、范围不断扩大的销售领导角色。布拉德利女士获得了得克萨斯大学达拉斯分校的表演艺术学士学位。
- Jeanina Bradley has served as Centinel's Vice President, U.S. Sales since May 2026. Ms. Bradley joined Centinel in July 2019 as a Regional Sales Manager and was subsequently promoted to Area Vice President, Mountain/Central in December 2021. Prior to joining Centinel, Ms. Bradley served as Vice President of Spine and Distributor Partner for Align Alternatives, a multistate spine and orthopedic distributor in the southern United States, from August 2014 to December 2018. From 2004 to 2014, Ms. Bradley served in different medical device and market development positions, including as Director of Development for Methodist Health System Moody Brain and Spine Institute in North Texas from August 2013 through August 2014, as a Spine Specialist for NuVasive, Inc. from March 2012 through July 2013, and as a Sales Associate and Territory Manager for Boston Scientific Corporation from October 2004 through March 2012. She has worked in sales, sales training, and marketing, as well as sales leadership roles of increasing responsibility and scope. Ms. Bradley received a B.A. in Performing Arts from The University of Texas at Dallas.
- Vincent Lesniewski
Vincent Lesniewski自2026年9月起担任Centinel医疗教育和临床账户副总裁。Lesniewski先生此前曾于2022年2月至2026年8月担任Centinel战略客户副总裁。Lesniewski先生于2018年4月加入Centinel，担任市场开发总监。在此之前，他曾在强生 — DePuy Synthes担任升级职务，包括2014年10月至2018年3月的Area Business Manager、Capital and Enabling Technologies以及2012年8月至2014年9月的prodisc sales全国总监。2004年至2012年，Lesniewski先生曾在Synthes Spine，Inc.担任不同职务，专注于prodisc产品组合，2010年至2012年担任临床销售，2007年至2010年担任临床专家，2004年至2007年担任prodisc产品经理，2001年至2004年担任生物材料和CMF产品经理。从2000年到2001年，Lesniewski先生担任Bionx肩部可吸收产品线产品经理。从1998年到2000年，Lesniewski先生担任EBI Spine脊柱融合刺激器产品经理。Lesniewski先生获得罗格斯大学化学学士学位。
Vincent Lesniewski has served as Centinel's Vice President, Medical Education and Clinical Accounts since September 2026. Mr. Lesniewski previously served as Centinel's Vice President, Strategic Accounts from February 2022 to August 2026. Mr. Lesniewski joined Centinel as Director, Market Development in April 2018. Prior to that, he held escalating roles at Johnson & Johnson—DePuy Synthes, including Area Business Manager, Capital and Enabling Technologies from October 2014 to March 2018 and National Director, prodisc Sales from August 2012 to September 2014. From 2004 to 2012, Mr. Lesniewski served in different positions with Synthes Spine, Inc., focused on the prodisc portfolio as Manager, Clinical Sales from 2010 to 2012, Clinical Specialist from 2007 to 2010, Product Manager for prodisc from 2004 to 2007 and for Biomaterials and CMF from 2001 to 2004. From 2000 to 2001, Mr. Lesniewski served as Product Manager, Shoulder Resorbable Product Line for Bionx. From 1998 to 2000, Mr. Lesniewski served as Product Manager, Spinal Fusion Stimulators for EBI Spine. Mr. Lesniewski received a B.A. in Chemistry from Rutgers University.- Vincent Lesniewski自2026年9月起担任Centinel医疗教育和临床账户副总裁。Lesniewski先生此前曾于2022年2月至2026年8月担任Centinel战略客户副总裁。Lesniewski先生于2018年4月加入Centinel，担任市场开发总监。在此之前，他曾在强生 — DePuy Synthes担任升级职务，包括2014年10月至2018年3月的Area Business Manager、Capital and Enabling Technologies以及2012年8月至2014年9月的prodisc sales全国总监。2004年至2012年，Lesniewski先生曾在Synthes Spine，Inc.担任不同职务，专注于prodisc产品组合，2010年至2012年担任临床销售，2007年至2010年担任临床专家，2004年至2007年担任prodisc产品经理，2001年至2004年担任生物材料和CMF产品经理。从2000年到2001年，Lesniewski先生担任Bionx肩部可吸收产品线产品经理。从1998年到2000年，Lesniewski先生担任EBI Spine脊柱融合刺激器产品经理。Lesniewski先生获得罗格斯大学化学学士学位。
- Vincent Lesniewski has served as Centinel's Vice President, Medical Education and Clinical Accounts since September 2026. Mr. Lesniewski previously served as Centinel's Vice President, Strategic Accounts from February 2022 to August 2026. Mr. Lesniewski joined Centinel as Director, Market Development in April 2018. Prior to that, he held escalating roles at Johnson & Johnson—DePuy Synthes, including Area Business Manager, Capital and Enabling Technologies from October 2014 to March 2018 and National Director, prodisc Sales from August 2012 to September 2014. From 2004 to 2012, Mr. Lesniewski served in different positions with Synthes Spine, Inc., focused on the prodisc portfolio as Manager, Clinical Sales from 2010 to 2012, Clinical Specialist from 2007 to 2010, Product Manager for prodisc from 2004 to 2007 and for Biomaterials and CMF from 2001 to 2004. From 2000 to 2001, Mr. Lesniewski served as Product Manager, Shoulder Resorbable Product Line for Bionx. From 1998 to 2000, Mr. Lesniewski served as Product Manager, Spinal Fusion Stimulators for EBI Spine. Mr. Lesniewski received a B.A. in Chemistry from Rutgers University.